Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440359 · ClinicalTrials.gov registry record · Phase 2
Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole
A Phase 2 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03440359: Completed Phase 2 study, sponsored by Eastern Virginia Medical School.
NCT03440359 is a Phase 2 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03440359, a Phase 2 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Aromatase inhibitors such as letrozole are hypothesized to maintain normal hypothalamic/ pituitary feedback mechanisms and in the case of OI (ovulation induction) in women with PCOS, may act to increase follicular sensitivity to FSH by increasing intrafollicular androgen levels. Letrozole also may act to increase midluteal P levels presumably by induction of follicles and corpora lutea. The investigators are asking the question whether P supplementation with Crinone (8%) may have an additive beneficial effect on endometrial development in those women taking letrozole. Progesterone levels in the endometrium (tissue levels) have been documented to be significantly higher than serum levels after vaginal administration which may lead to higher pregnancy rates. In addition P has been shown to decrease LH pulse frequency which is elevated in PCOS and has been shown to down regulate endometrial androgen receptors. There have been retrospective studies showing progesterone supplementation seems to benefit both CC and letrozole treatment groups. In fact, this study showed the only pregnancies in the letrozole group were those in women who took P supplementation. However the number of cycles studied was small. There is a place for a randomized controlled trial (RCT) to determine if luteal phase P supplementation with Crinone should be used in all women using letrozole for Ovulation Induction (OI) in combination with Intrauterine Insemination (IUI) or Timed Intercourse (TI). This is currently not done in all clinical practices.
Primary Outcome
The primary endpoint of the trial is the Clinical Pregnancy Rate per cycle initiated
Interventions
- DRUG Letrozole Oral Tablet
- DRUG Progesterone Vaginal Gel 8%
- DIAGNOSTIC_TEST pelvic ultrasound
- DRUG Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
- OTHER Intrauterine insemination or timed intercourse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-07-06 |
| Est. Completion | 2017-12-30 |
| Phase | Phase 2 |
What the finished NCT03440359 record still lists
NCT03440359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 5 interventions - of which Letrozole Oral Tablet is the first listed.
NCT03440359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03440359 about?
NCT03440359 is a clinical study titled "Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole". Aromatase inhibitors such as letrozole are hypothesized to maintain normal hypothalamic/ pituitary feedback mechanisms and in the case of OI (ovulation induction) in women with PCOS, may act to increase follicular sensitivity to FSH by increasing intrafollicular androgen levels. Letrozole also may a...
What is the current status of trial NCT03440359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2012-07-06. Estimated completion is 2017-12-30.
What interventions are being tested in trial NCT03440359?
The interventions under investigation include: Letrozole Oral Tablet (DRUG), Progesterone Vaginal Gel 8% (DRUG), pelvic ultrasound (DIAGNOSTIC_TEST), Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe (DRUG), Intrauterine insemination or timed intercourse (OTHER).
Who is sponsoring clinical trial NCT03440359?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03440359's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI